503A vs. 503B: what clinics actually need to know.
If the compounding landscape feels like unmapped terrain, you're not imagining it. Two labels — 503A and 503B — decide a lot about how a compounded preparation can be made, who it can ship to, and what your practice needs to order it. Here's the lay of the land, in plain English.
Where the 503A / 503B split came from
The two categories aren't arbitrary. They were created by the Drug Quality and Security Act of 2013 (DQSA) — Congress's response to a 2012 fungal meningitis outbreak traced to contaminated sterile preparations from the New England Compounding Center. The DQSA drew a clearer line between traditional, patient-specific compounding and larger-scale outsourcing facilities that register with and are inspected by the FDA. That history is worth knowing, because it's exactly why the two lanes carry very different oversight.
Two kinds of compounding pharmacy
Both 503A and 503B are named for sections of the federal Food, Drug, and Cosmetic Act, and both are legitimate, licensed parts of the pharmacy system. The difference is how they're allowed to operate — and under whose rules.
- 503A pharmacies compound patient-specific preparations against a valid prescription. They're regulated primarily by state boards of pharmacy and follow United States Pharmacopeia (USP) standards for compounding — USP <795> for non-sterile and USP <797> for sterile compounding — with FDA oversight of the compounding framework layered on top.
- 503B outsourcing facilities register with the FDA, are inspected on a risk-based schedule, and must follow current good manufacturing practice (cGMP) requirements under 21 CFR — the same category of manufacturing-quality rules that apply to larger-scale drug production. They can compound in batches for office use without a patient-specific prescription.
| 503A pharmacy | 503B outsourcing facility |
|---|---|
| Compounds patient-specific, against a valid prescription | Can produce larger batches for office use, without a per-patient prescription |
| Regulated by state boards of pharmacy; follows USP <795>/<797> | FDA-registered and inspected; follows cGMP under 21 CFR |
| Ships the patient-specific preparation (to patient or clinic, per the rules) | Ships office-use stock to clinics, hospitals, and physicians' offices |
Blue Atlas connects clinics to both — one portal to multiple licensed 503A and 503B pharmacies — which is the practical reason a single account can cover more of what a practice needs.
The line that trips people up: "compounded" is not "FDA-approved"
This matters, so here it is plainly: individual compounded preparations are not FDA-approved drugs. They're prepared by licensed 503A and 503B pharmacies under FDA oversight of compounding pharmacy operations — not reviewed product-by-product the way a mass-manufactured, FDA-approved drug is. That's a real, legitimate framework, and it's a different thing from an approved drug. Any source that blurs those two sentences is one to be careful with.
The prescriber requirement — the part clinics ask about most
Because compounded medications are prescription products, a legitimate account is gated to a licensed prescriber. The honest, important version:
You don't have to be the prescriber yourself — but your practice needs a licensed provider on file. Blue Atlas verifies eligibility with a valid NPI and a state license (the NPI checked against the national NPPES registry). A practice with no prescriber has no lawful ordering path — and the sources that pretend otherwise are exactly the ones drawing regulatory attention. If your practice is building toward peptide or wellness services and doesn't have a prescriber yet, the real solution is adding one (an MD, DO, or NP) or a telehealth prescriber pathway — not skipping the step. More on the prescriber requirement →
Why the "wild west" feeling is real — and what to do about it
The regulatory picture genuinely is shifting: the FDA has been active, and eligibility for specific bulk substances changes between review cycles. My job isn't to scare you about it or to claim anyone has "tamed" the market — it's to help you read the map. Some things are clearly established, some are in flux, and the honest move is to know which is which and source from licensed, verified channels. How to vet a supplier → · Reading a shifting compounding map →
Common questions
Are 503B pharmacies better than 503A?
Neither is “better” — they’re different tools. A 503B outsourcing facility registers with the FDA, is inspected, and follows current good manufacturing practice (cGMP) requirements, and it can supply office-use stock in batches. A 503A pharmacy compounds patient-specific preparations against a prescription, under state board of pharmacy oversight and United States Pharmacopeia (USP) standards. The right one depends on whether you need a patient-specific preparation or office-use stock — not on a quality ranking.
Are 503A compounding pharmacies safe?
A 503A compounding pharmacy operates under state board of pharmacy licensure and USP standards for compounding (USP <795> for non-sterile, USP <797> for sterile), within the FDA’s compounding framework. As with any pharmacy, quality depends on the specific pharmacy and how it operates — which is exactly why verifying a source’s licensure and sourcing matters more than the category label alone.
Can one company be both a 503A and a 503B?
Yes. A company can register a 503B outsourcing facility while also operating a 503A pharmacy, under the separate rules that govern each. What matters for a given order is which section that specific preparation actually runs through.
What can 503A and 503B pharmacies compound?
Both compound from eligible bulk drug substances — generally a component of an FDA-approved drug, a substance on a recognized pharmacopoeia, or one that has cleared the FDA’s bulk-substance review. Eligibility is decided substance-by-substance and changes over time, which is why current status matters before you build a service around any one substance.
Have a question about where your practice fits?
Ask me →Educational only — general regulatory framework, not legal or medical advice, and not specific to any one product. Compounded preparations are not FDA-approved drugs.